Literature DB >> 11331326

Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma.

D M Lillington1, I N Micallef, E Carpenter, M J Neat, J A Amess, J Matthews, N J Foot, B D Young, T A Lister, A Z Rohatiner.   

Abstract

PURPOSE: To assess whether pre-high-dose therapy (HDT)-related factors play a critical role in the development of therapy-related myelodysplasia (tMDS) or secondary acute myelogenous leukemia (sAML). PATIENTS AND METHODS: Twenty-nine of 230 patients with a primary diagnosis of non-Hodgkin's lymphoma (NHL) developed tMDS/sAML after HDT comprising cyclophosphamide and total-body irradiation (TBI) supported by autologous hematopoietic progenitor cells. G-banding and fluorescence in-situ hybridization (FISH) were used to detect clonal cytogenetic abnormalities.
RESULTS: The majority of patients showed complex karyotypes at diagnosis of tMDS/sAML containing, in particular, complete or partial loss of chromosomes 5 and/or 7. Using single locus-specific FISH probes, significant levels of clonally abnormal cells were found before HDT in 20 of 20 tMDS/sAML patients screened, compared with three of 24 patients screened who currently have not developed tMDS/sAML, at a median follow-up of 5.9 years after HDT.
CONCLUSION: Prior cytotoxic therapy may play an important etiologic role and may predispose to the development of tMDS/sAML. Using a triple FISH assay designed to detect loss of chromosomal material from 5q31, 7q22, or 13q14, significant levels of abnormal cells can be detected before HDT and may predict which patients are at increased risk of developing secondary disease. Further prospective evaluation of this FISH assay is warranted to determine its predictive power in this setting.

Entities:  

Mesh:

Year:  2001        PMID: 11331326     DOI: 10.1200/JCO.2001.19.9.2472

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

1.  Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature.

Authors:  Dan Yang; Xiaorui Fu; Xudong Zhang; Wencai Li; Mingzhi Zhang
Journal:  Oncol Lett       Date:  2015-09-15       Impact factor: 2.967

Review 2.  Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.

Authors:  Mojtaba Akhtari; Vijaya Raj Bhatt; Pavan Kumar Tandra; Jairam Krishnamurthy; Heidi Horstman; Amy Dreessen; Pei Xian Chen; James O Armitage
Journal:  Cancer Biol Ther       Date:  2013-10-18       Impact factor: 4.742

3.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Authors:  Richard A Nash; Peter A McSweeney; Leslie J Crofford; Muneer Abidi; Chien-Shing Chen; J David Godwin; Theodore A Gooley; Leona Holmberg; Gretchen Henstorf; C Fred LeMaistre; Maureen D Mayes; Kevin T McDonagh; Bernadette McLaughlin; Jerry A Molitor; J Lee Nelson; Howard Shulman; Rainer Storb; Federico Viganego; Mark H Wener; James R Seibold; Keith M Sullivan; Daniel E Furst
Journal:  Blood       Date:  2007-04-23       Impact factor: 22.113

4.  Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.

Authors:  Silvia Montoto; Janet Matthews; Paul Greaves; Debra Lillington; Deborah Anderson; John G Gribben; T Andrew Lister
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

5.  Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

Authors:  Christopher J Gibson; R Coleman Lindsley; Vatche Tchekmedyian; Brenton G Mar; Jiantao Shi; Siddhartha Jaiswal; Alysia Bosworth; Liton Francisco; Jianbo He; Anita Bansal; Elizabeth A Morgan; Ann S Lacasce; Arnold S Freedman; David C Fisher; Eric Jacobsen; Philippe Armand; Edwin P Alyea; John Koreth; Vincent Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Sarah Nikiforow; Stephen J Forman; Franziska Michor; Donna Neuberg; Ravi Bhatia; Smita Bhatia; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2017-01-09       Impact factor: 44.544

Review 6.  Second Malignancies after Hematopoietic Stem Cell Transplantation.

Authors:  Ivetta Danylesko; Avichai Shimoni
Journal:  Curr Treat Options Oncol       Date:  2018-02-08

Review 7.  Therapy-related myeloid neoplasms - what have we learned so far?

Authors:  Mohammad Faizan Zahid; Aric Parnes; Bipin N Savani; Mark R Litzow; Shahrukh K Hashmi
Journal:  World J Stem Cells       Date:  2016-08-26       Impact factor: 5.326

8.  Therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  Smita Bhatia
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

Review 9.  Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma.

Authors:  Gordon W Dewald
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

10.  Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.

Authors:  Bart Barlogie; Guido Tricot; Jeff Haessler; Frits van Rhee; Michele Cottler-Fox; Elias Anaissie; James Waldron; Mauricio Pineda-Roman; Raymond Thertulien; Maurizio Zangari; Klaus Hollmig; Abid Mohiuddin; Yazan Alsayed; Antje Hoering; John Crowley; Jeffrey Sawyer
Journal:  Blood       Date:  2007-09-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.